In the Commentary “How to Cure AIDS: Feeling the Elephant,” Guest Editor David Margolis, MD, University of North Carolina at Chapel Hill, states, “The breadth and diversity of reports found in the issue reflect the many domains of investigation that must be brought to bear to solve challenges of persistent HIV infection, and provide one of the critical missing tools needed to end the worldwide AIDS pandemic.”
HIV latency, in which reservoirs of virus persist despite effective antiretroviral therapy and are able to hide from existing anti-HIV drugs and the body’s immune defenses, is one of the greatest remaining challenges to achieving a cure. Guochun Jiang and Satya Dandekar, University of California, Davis, discuss the potential of one emerging “shock-and-kill” strategy to eradicate latent viral reservoirs in the Review article “Targeting NF-κB Signaling with Protein Kinase C Agonists As an Emerging Strategy for Combating HIV Latency.”
Zelda Euler and Galit Alter, Ragon Institute of Massachusetts General Hospital, MIT, and Harvard University (Cambridge, MA), present another latency reversal approach that uses “killer” monoclonal antibody-based drugs that can seek out and eliminate replication-competent HIV in combination with agents able to flush the virus out of its hiding places. The authors describe this novel strategy in the Review article “Exploring the Potential of Monoclonal Antibody Therapeutics for HIV-1 Eradication.”
“The HIV research community is turning its attention to a goal that seemed unimaginable not so long ago, the development of a cure for HIV/AIDS,” says Thomas Hope, PhD, Editor-in-Chief of AIDS Research and Human Retroviruses and Professor of Cell and Molecular Biology at Northwestern University, Feinberg School of Medicine, Chicago, IL. “To support that effort, we are focusing the first issue of 2015 on HIV cure related research and making the work available free to researchers and the public alike.”
About the Journal
AIDS Research and Human Retroviruses, published monthly in print and online, presents papers, reviews, and case studies documenting the latest developments and research advances in the molecular biology of HIV and SIV and innovative approaches to HIV vaccine and therapeutic drug research, including the development of antiretroviral agents and immune-restorative therapies. The content also explores the molecular and cellular basis of HIV pathogenesis and HIV/HTLV epidemiology. The Journal features rapid publication of emerging sequence information and reports on clinical trials of emerging HIV therapies. Tables of content and a sample issue may be viewed on the AIDS Research and Human Retroviruses website.
About the Publisher
Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including AIDS Patient Care and STDs, Viral Immunology, and Journal of Interferon & Cytokine Research. Its biotechnology trade magazine, Genetic Engineering & Biotechnology News (GEN), was the first in its field and is today the industry’s most widely read publication worldwide. A complete list of the firm’s 80 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website.